Zobrazit v EDS

Amyloid-PET imaging predicts functional decline in clinically normal individuals

Uloženo v:
Podrobná bibliografie
Název: Amyloid-PET imaging predicts functional decline in clinically normal individuals
Autoři: Quenon, Lisa, Collij, Lyduine E, den Braber, Anouk, Ritchie, Craig W, Boada, Mercè, Marquié, Marta, Vandenberghe, Rik, Luckett, Emma S, Schöll, Michael, Frisoni, Giovanni B, Buckley, Christopher, Stephens, Andrew, Garcia, David Vállez, Altomare, Daniele, Ford, Lisa, Birck, Cindy, Mett, Anja, Gismondi, Rossella, Wolz, Robin, Grootoonk, Sylke, Manber, Richard, Shekari, Mahnaz, Lhommel, Renaud, Lopes Alves, Isadora, Dricot, Laurence, Ivanoiu, Adrian, Farrar, Gill, Barkhof, Frederik, Hanseeuw, Bernard J, Consortium, AMYPAD, Gérard, Thomas, Malotaux, Vincent, Huyghe, Lara, Gispert, Juan Domingo, Jessen, Frank, Visser, Pieter Jelle
Přispěvatelé: UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Service de neurologie
Zdroj: Alzheimers Res Ther
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-13 (2024)
the AMYPAD Consortium 2024, 'Amyloid-PET imaging predicts functional decline in clinically normal individuals', Alzheimer's Research and Therapy, vol. 16, no. 1, 130. https://doi.org/10.1186/s13195-024-01494-9
Alzheimer's research & therapy 16(1), 130 (2024). doi:10.1186/s13195-024-01494-9
Alzheimer's research & therapy, Vol. 16, no. 1, p. 130 [1-13] (2024)
Informace o vydavateli: Springer Science and Business Media LLC, 2024.
Rok vydání: 2024
Témata: Male, Clinical Neurology, diagnostic imaging [Cognitive Dysfunction], metabolism [Amyloid beta-Peptides], Neurosciences. Biological psychiatry. Neuropsychiatry, THRESHOLD, Female [MeSH], Aged, 80 and over [MeSH], Brain/diagnostic imaging [MeSH], Cognitive Dysfunction/metabolism [MeSH], Aged [MeSH], Amyloid beta-Peptides/metabolism [MeSH], Humans [MeSH], Longitudinal Studies [MeSH], Functional decline, Middle Aged [MeSH], Cross-Sectional Studies [MeSH], Preclinical Alzheimer, Positron-Emission Tomography/methods [MeSH], Male [MeSH], Brain/metabolism [MeSH], Instrumental activities of daily living, Research, Cognitive Dysfunction/diagnostic imaging [MeSH], Activities of Daily Living [MeSH], Centiloid, Amyloid-PET, metabolism [Cognitive Dysfunction], Activities of Daily Living, Humans, AMYPAD Consortium, Cognitive Dysfunction, ddc:610, Longitudinal Studies, RC346-429, diagnostic imaging [Brain], 11 Medical and Health Sciences, Aged, Aged, 80 and over, Science & Technology, 42 Health sciences, Amyloid beta-Peptides, DEMENTIA, methods [Positron-Emission Tomography], Neurosciences, Brain, 32 Biomedical and clinical sciences, IMPAIRMENT, Middle Aged, 16. Peace & justice, 3. Good health, Cross-Sectional Studies, metabolism [Brain], Positron-Emission Tomography, INSTRUMENTAL ACTIVITIES, COGNITIVE DECLINE, Female, Neurosciences & Neurology, Neurology. Diseases of the nervous system, Life Sciences & Biomedicine, RC321-571
Popis: Background There is good evidence that elevated amyloid-β (Aβ) positron emission tomography (PET) signal is associated with cognitive decline in clinically normal (CN) individuals. However, it is less well established whether there is an association between the Aβ burden and decline in daily living activities in this population. Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established. Methods Cross-sectional and longitudinal analyses over a mean three-year timeframe were performed on the European amyloid-PET imaging AMYPAD-PNHS dataset that phenotypes 1260 individuals, including 1032 CN individuals and 228 participants with questionable functional impairment. Amyloid-PET was assessed continuously on the Centiloid (CL) scale and using Aβ groups (CL 50 = Aβ+). Functional abilities were longitudinally assessed using the Clinical Dementia Rating (Global-CDR, CDR-SOB) and the Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q). The Global-CDR was available for the 1260 participants at baseline, while baseline CDR-SOB and A-IADL-Q scores and longitudinal functional data were available for different subsamples that had similar characteristics to those of the entire sample. Results Participants included 765 Aβ- (61%, Mdnage = 66.0, IQRage = 61.0–71.0; 59% women), 301 Aβ± (24%; Mdnage = 69.0, IQRage = 64.0–75.0; 53% women) and 194 Aβ+ individuals (15%, Mdnage = 73.0, IQRage = 68.0–78.0; 53% women). Cross-sectionally, CL values were associated with CDR outcomes. Longitudinally, baseline CL values predicted prospective changes in the CDR-SOB (bCL*Time = 0.001/CL/year, 95% CI [0.0005,0.0024], p = .003) and A-IADL-Q (bCL*Time = -0.010/CL/year, 95% CI [-0.016,-0.004], p = .002) scores in initially CN participants. Increased clinical progression (Global-CDR > 0) was mainly observed in Aβ+ CN individuals (HRAβ+ vs Aβ- = 2.55, 95% CI [1.16,5.60], p = .020). Optimal thresholds for predicting decline were found at 41 CL using the CDR-SOB (bAβ+ vs Aβ- = 0.137/year, 95% CI [0.069,0.206], p bAβ+ vs Aβ- = -0.693/year, 95% CI [-1.179,-0.208], p = .005). Conclusions Amyloid-PET quantification supports the identification of CN individuals at risk of functional decline. Trial registration The AMYPAD PNHS is registered at www.clinicaltrialsregister.eu with the EudraCT Number: 2018-002277-22.
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 1758-9193
DOI: 10.1186/s13195-024-01494-9
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38886831
https://doaj.org/article/916789749e284220b7135dd30f36111c
https://hdl.handle.net/1871.1/54c58075-b99a-428d-98d4-1890d2935ff1
https://research.vu.nl/en/publications/54c58075-b99a-428d-98d4-1890d2935ff1
https://doi.org/10.1186/s13195-024-01494-9
https://cris.maastrichtuniversity.nl/en/publications/0af5d18d-00fb-499d-b18e-d52eb3a3f622
https://doi.org/10.1186/s13195-024-01494-9
https://research.vumc.nl/en/publications/f6445675-6cbd-46a9-ad67-6a03b8b854b4
https://pub.dzne.de/record/270307
https://lirias.kuleuven.be/handle/20.500.12942/749946
https://doi.org/10.1186/s13195-024-01494-9
https://hdl.handle.net/2078.1/296660
https://repository.publisso.de/resource/frl:6519631
https://discovery-pp.ucl.ac.uk/id/eprint/10194242/
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (http://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Přístupové číslo: edsair.doi.dedup.....74cc955856e5e9a42505eb61024cb51f
Databáze: OpenAIRE
Popis
Abstrakt:Background There is good evidence that elevated amyloid-β (Aβ) positron emission tomography (PET) signal is associated with cognitive decline in clinically normal (CN) individuals. However, it is less well established whether there is an association between the Aβ burden and decline in daily living activities in this population. Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established. Methods Cross-sectional and longitudinal analyses over a mean three-year timeframe were performed on the European amyloid-PET imaging AMYPAD-PNHS dataset that phenotypes 1260 individuals, including 1032 CN individuals and 228 participants with questionable functional impairment. Amyloid-PET was assessed continuously on the Centiloid (CL) scale and using Aβ groups (CL 50 = Aβ+). Functional abilities were longitudinally assessed using the Clinical Dementia Rating (Global-CDR, CDR-SOB) and the Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q). The Global-CDR was available for the 1260 participants at baseline, while baseline CDR-SOB and A-IADL-Q scores and longitudinal functional data were available for different subsamples that had similar characteristics to those of the entire sample. Results Participants included 765 Aβ- (61%, Mdnage = 66.0, IQRage = 61.0–71.0; 59% women), 301 Aβ± (24%; Mdnage = 69.0, IQRage = 64.0–75.0; 53% women) and 194 Aβ+ individuals (15%, Mdnage = 73.0, IQRage = 68.0–78.0; 53% women). Cross-sectionally, CL values were associated with CDR outcomes. Longitudinally, baseline CL values predicted prospective changes in the CDR-SOB (bCL*Time = 0.001/CL/year, 95% CI [0.0005,0.0024], p = .003) and A-IADL-Q (bCL*Time = -0.010/CL/year, 95% CI [-0.016,-0.004], p = .002) scores in initially CN participants. Increased clinical progression (Global-CDR > 0) was mainly observed in Aβ+ CN individuals (HRAβ+ vs Aβ- = 2.55, 95% CI [1.16,5.60], p = .020). Optimal thresholds for predicting decline were found at 41 CL using the CDR-SOB (bAβ+ vs Aβ- = 0.137/year, 95% CI [0.069,0.206], p bAβ+ vs Aβ- = -0.693/year, 95% CI [-1.179,-0.208], p = .005). Conclusions Amyloid-PET quantification supports the identification of CN individuals at risk of functional decline. Trial registration The AMYPAD PNHS is registered at www.clinicaltrialsregister.eu with the EudraCT Number: 2018-002277-22.
ISSN:17589193
DOI:10.1186/s13195-024-01494-9